Analysis of Stock Sale Signal by Enliven Therapeutics (ELVN) Director Heyman
Unlock More Features
Login to access AI-powered analysis, deep research reports and more advanced features
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
Related Stocks
| Item | Data |
|---|---|
Insider |
Richard A. Heyman (Director) |
Transaction Date |
January 9, 2026 |
Number of Shares Sold |
4,285 Shares |
Sale Price |
$25.00 (Weighted Average Price) |
Total Transaction Value |
$107,125 |
Transaction Type |
Automatic Sell |
According to public data [1][2], Heyman conducted this sale through his trust account (The Richard A. Heyman and Anne E Daigle Trust), which falls under the scope of a prearranged 10b5-1 trading plan.
This sale occurred during a period of strong stock price growth [0]:
- 1-Month Gain: +50.75%
- 3-Month Gain: +31.92%
- Year-to-Date (YTD) Gain: +73.94%
- Post-Sale Performance: The stock price rose from $25.00 to $27.03, representing an8.1% increase
From a technical analysis perspective, ELVN is currently in a
As a clinical-stage biotechnology company, Enliven Therapeutics demonstrates a
- Current Ratio: 32.95x (extremely strong short-term solvency)
- Liability Risk: Low-risk rating
- Current Stock Price: $27.03, Market Capitalization: $1.604 Billion
| Factor | Analysis |
|---|---|
Limited Transaction Scale |
The $107,125 sale amount accounts for a small proportion of the shares Heyman may hold, so it does not constitute a major sell-off signal [1] |
Prearranged Trading Plan |
This is part of a 10b5-1 automatic sale plan, which typically indicates a pre-set risk diversification strategy rather than a negative judgment on the company |
Stock Price Rise After Sale |
The stock price rose 8.1% after the sale, indicating strong market demand, and the insider sale did not trigger selling pressure |
| Factor | Analysis |
|---|---|
Profit-Taking Timing |
The sale price of $25.00 is close to the recent high, which may reflect the insider’s judgment that short-term valuation is already satisfactory |
No Concurrent Share Purchases |
Apart from this sale, there have been no share repurchases or purchases by Heyman or other directors during the same period |
Upcoming Phase 3 CML Trial |
The company’s core pipeline ELVN-001 for the treatment of chronic myeloid leukemia (CML) is scheduled to enter Phase 3 trials in 2026 [3]. Some insiders may choose to take partial profits ahead of this key milestone |
Wall Street maintains a
| Indicator | Data |
|---|---|
Consensus Rating |
Buy (100% of analysts recommend Buy) |
Median Target Price |
$39.00 |
Target Price Range |
$39.00 - $52.00 |
Upside Potential |
+44.3% |
- Moderate Sale Scale: The $107,000 sale amount has limited impact on a company with a $1.6 billion market capitalization
- Compliant with Prearranged Plan: This is a regular asset allocation and risk diversification arrangement
- Stock Performance Confirms Confidence: The stock price continued to rise after the sale, indicating that market confidence in the company’s prospects remains unshaken
| Focus Area | Explanation |
|---|---|
Core Catalyst |
Phase 3 clinical data of ELVN-001 for CML (expected in 2026) |
Valuation Rationality |
The current P/B ratio is 3.53x, which is within a reasonable range considering the characteristics of a clinical-stage biotechnology company |
Risk Warning |
The short-term RSI of the stock is overbought, which may lead to a technical pullback |
[1] NASDAQ - Enliven Therapeutics Insider Activity (https://www.nasdaq.com/market-activity/stocks/elvn/insider-activity)
[2] StockTitan - Enliven Therapeutics Inc. Insider Trading Activity (https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-bfb2c29f222a.html)
[3] Seeking Alpha - Enliven Therapeutics: Notable Early Signals (https://seekingalpha.com/article/4844990-enliven-therapeutics-notable-early-signals-but-still-too-many-assumptions-to-justify-the-buy)
[0] Jinling AI Financial Database (Company Profile, Stock Price Data, Technical Analysis)
Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.